Interferon alpha kinoid (Neovacs)(Interferon alpha kinoid (Neovacs)) - 药物靶点：IFN α x IFNAR_在研适应症：系统性红斑狼疮_专利_临床

概要

基本信息

药物类型

干扰素

别名

IFNalpha kinoid vaccine Neovacs、IFNalphakinoid、IFNkinoid

+ [6]

靶点

IFN α x IFNAR

作用机制

IFNA抑制剂(干扰素α抑制剂)、IFNAR激动剂(干扰素α/β受体复合体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Department Immunology of Diabetes at Hospital Cochin百缮药业（苏州）有限公司

Sanofi Pasteur

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

5

项与 Interferon alpha kinoid (Neovacs) 相关的临床试验

NCT02980198 / Withdrawn临床2期

A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis

This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis

开始日期2017-05-03

申办/合作机构

Neovacs SA

EUCTR2015-001341-86-BG / Not yet recruiting临床2期

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNa-Kinoid in Adult Subjects with Systemic Lupus Erythematosus - Phase IIb study of IFN-K in Systemic Lupus Erythematosus

开始日期2017-04-10

申办/合作机构-

NCT02665364 / Terminated临床2期

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

The safety and immunogenicity of the IFNα-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with Systemic Lupus Erythematosus (SLE). Preliminary results showed acceptable safety profile and patients developped antibodies response.
The principal aim of the present study is to confirm the neutralization of the interferon gene signature and the clinical efficacy of IFN-K in subjects with SLE. In addition, the immune responses and the safety elicited by IFN-K will also be evaluated.

开始日期2015-09-23

申办/合作机构

Neovacs SA

100 项与 Interferon alpha kinoid (Neovacs) 相关的临床结果

登录后查看更多信息

100 项与 Interferon alpha kinoid (Neovacs) 相关的转化医学

登录后查看更多信息

100 项与 Interferon alpha kinoid (Neovacs) 相关的专利（医药）

登录后查看更多信息

8

项与 Interferon alpha kinoid (Neovacs) 相关的文献（医药）

2024-08-01·Marine Pollution Bulletin

Preliminary assessment of microplastic in rhizosphere and non-rhizosphere region of mangrove at four locations along Karachi coast, Pakistan

Article

作者: Alvi, Sofia Khalique ; Riaz, Shagufta ; Sahar, Rafia ; Rasool, Sarwat Ghulam ; Shafique, Seema ; Qader, Irfana ; Siddiqui, Pirzada J A ; Burhan, Zaib-Un-Nisa

Mangrove ecosystem faces significant threats from the various pollutants including microplastic (MPs). The aim of this study was to assess variations in MP distribution in mangrove sediments of rhizosphere (R) and non-rhizosphere (NR) regions. A total of 14,960 MP particles were identified from Sandspit backwater (SS-1 & SS-2) and Creek areas (PQ & KC). Notably, the NR showed higher MP counts (7848) compared to the R region (7112). Analysis revealed variations in MP types, with beads being predominant in both R and NR, followed by film, fiber, and fragments. KC exhibited highest MP contamination, followed by PQ, SS-2, and SS-1. Fourier-transform infrared (FTIR) analysis confirmed the presence of polyethylene terephthalate and polyethylene in sediments samples. This first detailed report on MP in mangrove sediments and other limited studies from Pakistan establishes the widespread distribution of MPs in the coastal area and provide a baseline for further elaboration in future.

2016-10-01·Rheumatology2区 · 医学

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study

2区 · 医学

Article

作者: Frédéric A. Houssiau ; Thérèse Croughs ; Julie Ducreux ; Pierre Vandepapelière ; Géraldine Grouard-Vogel ; François Spertini ; Camille Roucairol ; Estibaliz Lazaro ; Bernard R. Lauwerys ; Christian Jorgensen ; Marion Laborie ; Fabien Colaone

OBJECTIVEIFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNα Abs antibodies (Abs), and gene expression profiling.METHODSSerum and whole blood RNA samples were obtained in IFN-K-treated patients included in the follow-up study, in order to determine binding and neutralizing anti-IFNα Ab titres, and perform high-throughput transcriptomic studies.RESULTSNeutralization studies of 13 IFNα subtypes demonstrated the polyclonal nature of the Ab response induced by IFN-K. Follow-up analyses in six patients confirmed a significant correlation between neutralizing anti-IFNα Ab titres and decrease in IFN scores compared to baseline. These analyses also revealed an inhibitory effect of IFNα blockade on the expression of B cell associated transcripts.CONCLUSIONSIFN-K induces a polyclonal anti-IFNα response that decreases IFN- and B cell-associated transcripts.TRIAL REGISTRATIONClinicalTrials.gov, clinicaltrials.gov, NCT01058343.

2014-07-01·Journal of Animal Science2区 · 农林科学

Use of a stair-step compensatory gain nutritional regimen to program the onset of puberty in beef heifers1

2区 · 农林科学

Article

作者: Keisler, D. H. ; Williams, G. L. ; Park, C. S. ; Amstalden, M. ; Tedeschi, L. O. ; Thorson, J. F. ; Prezotto, L. D. ; Alves, B. R. C. ; Cardoso, R. C.

It was hypothesized that metabolic programming of processes underlying puberty can be shifted temporally through the use of a stair-step compensatory growth model such that puberty is optimally timed to occur at 11 to 12 mo of age. Forty crossbred beef heifers were weaned at approximately 3.5 mo of age and, after a 2-wk acclimation period, were assigned randomly to 1 of 4 nutritional groups: 1) low control (LC), restricted feed intake of a forage-based diet to promote BW gain of 0.5 kg/d until 14 mo of age, 2) high control (HC), controlled feed intake of a high-concentrate diet to promote BW gain of 1 kg/d until 14 mo of age, 3) stair-step 1 (SS-1), ad libitum feed intake of a high-concentrate diet until 6.5 mo of age followed by restricted access to a high-forage diet to promote BW gain of 0.35 kg/d until 9 mo of age, ad libitum feed intake of a high-concentrate diet until 11.5 mo of age, and restricted intake of a high-forage diet to promote BW gain of 0.35 kg/d until 14 mo of age, and 4) stair-step 2 (SS-2), reverse sequence of SS-1, beginning with restricted access to a high-forage diet. Body weight (every 2 wk) and circulating concentrations of leptin (monthly) were determined throughout the experiment. Concentrations of progesterone in blood samples collected twice weekly beginning at 8 mo of age were used to determine pubertal status. Body weight gain followed a pattern similar to that proposed in our experimental design. Circulating concentrations of leptin increased following distinct elevations in BW but decreased abruptly after feed intake restriction. Survival analysis indicated that the percentage of pubertal heifers in the LC group was lower (P < 0.05) than all other groups throughout the experiment. Although heifers in SS-1 were nutritionally restricted between 6.5 and 9 mo of age, the proportion pubertal by 12 mo of age did not differ (P = 0.36) from that of the HC group, with 80% and 70% pubertal in SS-1 and HC, respectively. In contrast, the proportion of heifers pubertal by 12 mo of age in the SS-2 group (40%) was lower (P < 0.05) than both HC and SS-1. However, by 14 mo of age, 90% of heifers in the SS-2 group had also attained puberty compared to only 40% of the LC group. In summary, these data provide evidence that changes in the nutritional and metabolic status during the early juvenile period can program the onset of puberty that occurs months later, allowing optimal timing of sexual maturation in replacement beef heifers.

100 项与 Interferon alpha kinoid (Neovacs) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性红斑狼疮	临床2期	格鲁吉亚	Neovacs SA	2015-08-22
1型糖尿病	临床2期	法国	Neovacs SA	-
1型糖尿病	临床2期	法国	Department Immunology of Diabetes at Hospital Cochin	-
皮肌炎	药物发现	瑞士	Neovacs SA	2017-05-03
皮肌炎	药物发现	德国	Neovacs SA	2017-05-03
皮肌炎	药物发现	意大利	Neovacs SA	2017-05-03
皮肌炎	药物发现	法国	Neovacs SA	2017-05-03
系统性红斑狼疮	药物发现	格鲁吉亚	Neovacs SA	2015-08-22
HIV感染	药物发现	法国	Sanofi Pasteur	-
干燥综合征	药物发现	法国	Neovacs SA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02665364 (CTgov)	临床2期	系统性红斑狼疮	185	Placebo+ISA 51 VG	襯簾鬱製淵襯積蓋膚鹹(遞鏇簾鏇淵壓鹹壓蓋艱) = 齋窪醖淵鏇構艱鏇廠願餘鏇顧鏇鬱鹹鑰繭鏇夢 (願憲襯獵廠蓋範繭廠鑰, 醖獵廠鏇蓋餘糧餘鹹遞 ~ 壓蓋膚鏇鏇鹹衊廠艱繭) 更多	-	2020-03-26
NCT02665364 (Pubmed \| Arthritis Rheumatol) 人工标引	临床2期	系统性红斑狼疮	185	IFN-α kinoid	(糧窪夢遞獵艱衊醖繭醖) = 糧構觸廠衊繭襯遞願蓋齋顧網鹹壓齋廠築積齋 (醖憲鏇淵製鏇廠齋襯窪 ) 更多	积极	2020-03-01
NCT02665364 (Pubmed \| Arthritis Rheumatol) 人工标引	临床2期	系统性红斑狼疮	185	Placebo	(糧窪夢遞獵艱衊醖繭醖) = 壓艱膚獵獵繭淵簾網簾齋顧網鹹壓齋廠築積齋 (醖憲鏇淵製鏇廠齋襯窪 ) 更多	积极	2020-03-01